Go Nakajima
About
Go Nakajima is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Go Nakajima has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Go Nakajima's work include Colorectal Cancer Treatments and Studies (18 papers), Gastric Cancer Management and Outcomes (9 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Go Nakajima is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Gastric Cancer Management and Outcomes (9 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Go Nakajima collaborates with scholars based in Japan, United States and Spain. Go Nakajima's co-authors include Jingfang Ju, Yaguang Xi, Kenji Kudo, Kazuhiko Hayashi, Elaine Gavin, Masakazu Yamamoto, Kazuhiko Hayashi, Hidekazu Kuramochi, Yuusuke Uchida and Ken Takasaki and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Neurology Neurosurgery & Psychiatry.
In The Last Decade
Go Nakajima
33 papers receiving 1.1k citations
Peers
Go Nakajima
Satoshi Takatsuka Japan
Ivy H.N. Wong Hong Kong
Susheng Shi China
Caterina Vicentini Italy
Mitsuru Miyachi Japan
Kazuma Sakuraba Japan
Samantha Bersani Italy
Veit Scheble Germany
Saori Ushijima United Kingdom
Citations per year, relative to Go Nakajima Go Nakajima (= 1×)
peers
Satoshi Takatsuka
Countries citing papers authored by Go Nakajima
Since
Specialization
Citations
This map shows the geographic impact of Go Nakajima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Go Nakajima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Go Nakajima more than expected).
Fields of papers citing papers by Go Nakajima
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Go Nakajima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Go Nakajima. The network helps show where Go Nakajima may publish in the future.
Co-authorship network of co-authors of Go Nakajima
This figure shows the co-authorship network connecting the top 25 collaborators of Go Nakajima. A scholar is included among the top collaborators of Go Nakajima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Go Nakajima. Go Nakajima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Izumo, Wataru, et al.. (2023). A Case of Pathologically Complete Response After Nivolumab Combined with Chemotherapy in a Gastric Cancer Patient with Virchow’s Lymph Node Metastasis. Clinical and Experimental Gastroenterology. Volume 16. 107–115.
2.
Satomi, Eriko, et al.. (2020). A Case of Abdominal Fullness Caused by a Retroperitoneal Bulky Tumor Treated with Epidural Analgesia. Gan to kagaku ryōhō. 47(11). 1615–1617.
3.
Kuramochi, Hidekazu, Go Nakajima, Kazuhiko Hayashi, Tatsuo Araida, & Masakazu Yamamoto. (2019). Amphiregulin/epiregulin mRNA Expression and Primary Tumor Location in Colorectal Cancer. Anticancer Research. 39(9). 4729–4736.
4.
Kuramochi, Hidekazu, Masayuki Ando, Michio Itabashi, et al.. (2017). Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Cancer Chemotherapy and Pharmacology. 79(3). 579–585.
5.
Kuramochi, Hidekazu, et al.. (2017). Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1. Oncology Letters. 14(1). 930–936.
6.
Kuramochi, Hidekazu, Ayako Nakamura, Go Nakajima, et al.. (2016). PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study. BMC Cancer. 16(1). 366–366.
7.
Nishina, Tomohiro, Toshikazu Moriwaki, Mitsuo Shimada, et al.. (2015). Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study). Clinical Colorectal Cancer. 15(3). 236–242.
8.
Nakajima, Go, Takuji Yamada, Kenji Kudo, et al.. (2014). HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report.. PubMed. 34(2). 867–72.
9.
Shimada, Mitsuo, Tomohiro Nishina, Jun Higashijima, et al.. (2014). Bevacizumab (Bmab) in combination with uracil-tegafur (UFT) and oral leucovorin (LV) in elderly patients (≥ 75 years old) with metastatic colorectal cancer (mCRC): A multicenter phase II trial (J-BLUE study).. Journal of Clinical Oncology. 32(3_suppl). 588–588.
10.
Nakamura, Ayako, Go Nakajima, Ryuji Okuyama, et al.. (2013). Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer. 17(1). 188–195.
11.
Kitagawa, Koichi, Go Nakajima, Hidekazu Kuramochi, Shun‐ichi Ariizumi, & Masakazu Yamamoto. (2013). Lymphatic vessel endothelial hyaluronan receptor-1 is a novel prognostic indicator for human hepatocellular carcinoma. Molecular and Clinical Oncology. 1(6). 1039–1048.
12.
Kaneko, Yuka, Hidekazu Kuramochi, Go Nakajima, Yoshimasa Inoue, & Masakazu Yamamoto. (2013). Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. International Journal of Clinical Oncology. 19(1). 113–120.
13.
Kuramochi, Hidekazu, Go Nakajima, Yuka Kaneko, et al.. (2012). Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer. 12(1). 88–88.
14.
Nakamura, Ayako, Kazuhiko Hayashi, Go Nakajima, et al.. (2011). Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer. Experimental and Therapeutic Medicine. 2(6). 1097–1103.
15.
Kuramochi, Hidekazu, et al.. (2010). Drug Monitoring During FOLFOX6 Therapy in a Rectal Cancer Patient on Chronic Hemodialysis. Japanese Journal of Clinical Oncology. 40(4). 360–364.
16.
Kuramochi, Hidekazu, Kazuhiko Hayashi, Go Nakajima, et al.. (2009). Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. Cancer Chemotherapy and Pharmacology. 65(5). 825–831.
17.
Kuramochi, Hidekazu, Kazuhiko Hayashi, Yuusuke Uchida, et al.. (2008). High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemotherapy and Pharmacology. 63(1). 85–89.
18.
Xi, Yaguang, Go Nakajima, Elaine Gavin, et al.. (2007). Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 13(10). 1668–1674.
19.
Uchida, Yuusuke, Kazuhiko Hayashi, Hidekazu Kuramochi, et al.. (2007). Combination therapy of S-1 and CDDP for patients with colorectal cancer. Journal of Cancer Research and Clinical Oncology. 133(11). 841–846.
20.
Xi, Yaguang, Go Nakajima, John C. Schmitz, Edward Chu, & Jingfang Ju. (2006). Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 7(1). 68–68.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Satoshi Takatsuka Breakdown of academic impact, for papers by Ivy H.N. Wong Breakdown of academic impact, for papers by Susheng Shi Breakdown of academic impact, for papers by Caterina Vicentini Breakdown of academic impact, for papers by Mitsuru Miyachi Breakdown of academic impact, for papers by Kazuma Sakuraba Breakdown of academic impact, for papers by Samantha Bersani Breakdown of academic impact, for papers by Veit Scheble Breakdown of academic impact, for papers by Saori Ushijima